Komo Biosciences

KOMO Biosciences is a non-viral targeted DNA insertion company developing platform technologies that enable the precise integration of large genetic payloads into defined genomic locations. Through its proprietary KOMbine™ and KOMbineX™ platforms, KOMO provides foundational genome engineering infrastructure for applications across therapeutics, bioprocessing, agricultural biotechnology, and industrial life sciences. KOMO’s mission is to enable the next generation of biological innovation by giving developers greater control over where, how, and what is added to the genome. Rather than focusing on gene editing, KOMO focuses on gene addition, making it possible to build more complex, scalable, and predictable biological systems. KOMO’s platforms are non-viral and non-nuclease and are designed to insert large genetic payloads without relying on unprotected double-strand DNA breaks or error-prone cellular repair pathways. This approach addresses key limitations of conventional genome engineering methods, including variability, low efficiency, and constraints on cargo size. Across the life sciences, innovators face common challenges: accelerating development timelines, simplifying manufacturing workflows, and achieving precise and durable genome integration at scale. KOMO’s technologies are built to solve these foundational problems, enabling faster design-test cycles and more reliable deployment of advanced biological systems. KOMO does not develop therapeutics internally. Instead, the company works through licensing agreements and strategic partnerships to provide the enabling genome engineering layer that supports therapeutic developers, agricultural innovators, industrial biotechnology companies, and government agencies in bringing next-generation solutions to market.